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PsoriasisPsoriasis is an autoimmunedisease,which symptoms can signiﬁcantly impair the patient's life quality. It ismainly
diagnosed through the visual inspection of the lesion skin by experienced dermatologists. Currently no cure for
psoriasis is available due to limited knowledge about its pathogenesis and development mechanisms. Previous
studies have proﬁled hundreds of differentially expressed genes related to psoriasis, however with no robust
psoriasis prediction model available. This study integrated the knowledge of three feature selection algorithms
that revealed 21 features belonging to 18 genes as candidate markers. The ﬁnal psoriasis classiﬁcation model
was established using the novel Incremental Feature Selection algorithm that utilizes only 3 features from 2
unique genes, IGFL1 and C10orf99. This model has demonstrated highly stable prediction accuracy (averaged
at 99.81%) over three independent validation strategies. The two marker genes, IGFL1 and C10orf99, were
revealed as the upstream components of growth signal transduction pathway of psoriatic pathogenesis.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Psoriasis is a widely spread chronic autoimmune disease withmajor
symptoms on skins and joints [1,2]. Psoriasis may increase the risks of
stroke and myocardial infarction [3,4] and shares the same effective
drug, p40-neutralizing antibodies, with the neurodegenerative
Alzheimer's disease [5]. The prevalence of psoriasis varies considerably
in different geographic regions and ethnic groups, with higher rate in
the Caucasian population (e.g. 2.2% in the United States) and lower
rate in the Asian (e.g. less than 1% in China) [6,7]. Along with the
cutaneous manifestations, psoriasis is accompanied by inﬂammatory ar-
thritis in up to 40% cases [8]. Its phenotypic symptoms may also include
epidermal hyperplasia, keratinocyte differentiations, angiogenesis, inﬁl-
tration of T lymphocytes, dendritic cells, neutrophils, cytokines as well
as chemokines [9–11]. The current diagnosis of psoriasis heavily relies
on the visual observation of the skin lesion biopsy by an experienced
dermatologist [12], which procedure is inefﬁcient and labor intensive.tutes of Advanced Technology,
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ghts reserved.Majority of the large-scale psoriasis studies have employed microar-
ray or qPCR techniques to compare the gene expression pattern in psori-
atic lesion sampleswith healthy controls. Gudjonsson et al. systematically
screened ~54,000 probe sets in the Affymetrix HG-U133 Plus 2 platform,
and detected 179 unique genes for 223 probe sets with differential
expression in the uninvolved psoriatic skin samples [13]. The lipidmetab-
olism was demonstrated to be most associated with psoriasis, and three
lipid metabolic related transcription factors, peroxisome proliferator-
activator receptor alpha (PPARA), sterol regulatory element-binding
protein (SREBF), and estrogen receptor 2 (ESR2), seem to regulate the
dysregulated genes in the uninvolved psoriatic samples. Reischl et al.
chose the Affymetrix HG-U133A platform to proﬁle the expression pat-
terns of ~22,000 probe sets in the human genome, and detected 179
genes for 203 probe sets with more than 2-fold expression changes in
the psoriatic lesion skins [14]. Their data strongly suggested that the
stemcell proliferation regulationWntpathway is associatedwith thepso-
riasis development. But it still remains elusive whether theWnt pathway
plays a causative role or merely the human immune response to the pso-
riatic lesion. Thehuman immune response to the environmental stimulus,
the type I interferon system,was screened in both the psoriatic lesion and
uninvolved skin samples on the AffymetrixHG-U133 Plus 2 platform [15].
There were 1408 up-regulated and 1465 down-regulated probe sets
detected in the psoriatic lesion skin samples, among which multiple T
cell marker genes and two type I interferon inducible genes (STAT1 and
ISG15) had ~3 fold or higher in expression changes. Swindell et al.
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samples betweenhuman andmouse. The calculated lists of top 5000 fold-
change ranked up-regulated anddown-regulated probe sets showed con-
sistent overlaps among different mouse psoriasiform phenotypes. Unfor-
tunately, the lists of marker genes barely overlapped between different
studies, leaving little information to construct a psoriatic classiﬁcation
model.
We hypothesized that a robust disease classiﬁcation model can be
constructed based on marker genes. This study employed the microarray
based gene expression proﬁles, in which three widely-used feature selec-
tion algorithms were applied to screen the psoriasis associated features
(probe sets). Majority of the 21 features were known to be associated
with psoriasis. We further conducted a comprehensive performance
evaluation of the neural network based binary classiﬁers trained with
the Incremental Feature Selection strategy. The classiﬁer based on the
three features of IGFL1 and C10orf99 outperformed the rest of models,
with over 99.43% accuracy in all three validation tests.
2. Methods
2.1. Data collection and preprocessing
Twomicroarray data sets with accession numbers GSE14905 [15] and
GSE13355 [16,17] were retrieved from the Gene Expression Omnibus
(GEO) Database [18]. The two data sets provide gene expression proﬁles
for the same disease type (psoriasis) and the corresponding controls,
but have no overlap of samples. This makes them an ideal paired set for
detecting the consistent psoriasis biomarkers. There are 176 participating
subjects in total, including 91 psoriatic patients and 85 healthy controls,
denoted by P = {P1, P2,…, P91} and N = {N1, N2,…, N85}. Samples from
both data setswere processed by the standard protocol for the Affymetrix
Human Genome U133 Plus 2.0 platform. The detailed information of the
samples used in this study is listed in the Supplementary Table S1.
The raw ﬂuorescence intensity data within CEL ﬁles were processed
by background correction, log2 transformation, and quantile normaliza-
tion using the Robust Multichip Analysis (RMA) algorithm [19], as im-
plemented in the program Affymetrix Expression Console™, which
was downloaded from http://www.affymetrix.com/estore/index.jsp.
The systematic batch biases were corrected by the Distance Weighted
Discrimination (DWD) algorithm [20]. DWD eliminates source effects
across different studies by ﬁnding a hyper-plane that separates the
two systematic biases and adjusts the microarray data by projecting
them on the hyper-plane through subtracting out the DWD plane
multiplied by the batch mean.
We removed the probe sets with less discriminating power by
measuring the overall variance. This procedure was performed in
varFilter of the R package Bioconductor geneﬁlter. We chose the default
setting of the Inter-Quartile Range function IQR for the parameter
var.func, and .5 as the var.cutoff. The function IQR was chosen for its
robust outlier detection. This ﬁltering step was applied on the DWD-
processed data sets, and 27,336 probe sets of the 176 participating
subjects were retained for further analysis.
This study investigated the binary classiﬁcation problem between
N1 = 91 psoriatic patients and N2 = 85 healthy controls. The total
number of samples was N = 91 + 85 = 176. The expression level of
each probe set was denoted as Fi, where i ϵ {1, 2,…, 27,336}. The follow-
ing sections aimed to detectm features Fj′, where j ϵ {1, 2,…,m} from the
M = 27,336 features of the binary classiﬁcationmodel.We investigated
various feature selection algorithms to detect psoriasis related features
from 27,336 probe sets, with classiﬁcation accuracy as the most
important feature. The following three algorithms were chosen for
their complementary performance features. ROC screens for the most
signiﬁcant phenotype-associated individual features, by investigating
each feature's parameter-independent association [21]. SVM-RFE fur-
ther optimizes the inter-feature associations, which can top-rank the
important features that have weak individual phenotype-association[22]. Boruta removes the featureswith less contribution to classiﬁcation
accuracy by introducing random variables for the competition [23,24].
We believe, the consensus features derived from the three algorithms
represent a reliable list of biomarker candidates. The R implemented
version of the three algorithms was used in this study.2.2. SVM-RFE feature selection algorithm
SVM-RFE is a Recursive Feature Elimination (RFE) strategy utilizing
the weight vector produced by the classiﬁcation model Support Vector
Machine [25]. RFE is a widely used strategy that can recursively reduce
the number of features by removing those features with the least
phenotype correlation rankings [22,26,27]. The Support VectorMachine
algorithmwas invented by Vladimir N Vapnik in 1979 for the classiﬁca-
tion problem [28], and it produces aweight vector for the input features
after being trained to optimize the classiﬁcation accuracy between the
psoriatic and healthy samples. The generated weight vector will be
used to rank the features, and the RFE strategywill recursively eliminate
the least ranked features. The R package mSVM-RFE was chosen as the
implementation of this algorithm [22].2.3. ROC feature selection algorithm
The receiver operating characteristic (ROC) is a graphical plot in the
signal detection theory that illustrates the relationship between the true
positive rate (TPR) versus the false positive rate (FPR) of a binary
classiﬁer [29]. The ROC curve is one of the best measurements to rank
the features between multiple groups of tissues [30]. We ranked the
features based on the ROC-based binary classiﬁcation performance of
the psoriatic and healthy samples. In brief, the two expression distribu-
tions of a given feature and/or genewere calculated for the psoriatic and
healthy samples, respectively. Next, the area under the ROC curve
(AUC) was calculated to rank the features. The R package rocc was
used as the implementation of this algorithm [21].2.4. Boruta feature selection algorithm
The Boruta feature selection algorithm is a random forest based
wrapper strategy that removes features proven to be less informative
than random probes [31]. The classiﬁcation algorithm, random forest,
was chosen because of its inexpensive calculation and parameter free
for manual tuning. A random forest [22] collects votes over multiple
decision tree based weak classiﬁers, which are independently trained
over the binary classiﬁcation data set between the psoriatic and healthy
samples. The importance of a probe set is measured by how the classiﬁ-
cation performance is decreased due to the random permutation of the
probe set among samples. The trained random forest classiﬁer provides
an importance estimate for all features [22]. The R package implementa-
tion of Boruta was used for this study [24].2.5. Classiﬁcation model
This study utilized a feed-forward neural network classiﬁerwith one
hidden layer of nodes [32] to distinguish the psoriatic samples from the
healthy controls. A neural network is amathematicalmodelwith a func-
tion f : X→ Y, where X is a collection of input neurons and Y is a collec-
tion of output neurons. X = {Fj′}, where j ϵ {1, 2,…, m}, is the features
selected by the aforementioned feature selection algorithms. There are
two output nodes, Y = {0, 1}, representing the predicted results of a
healthy or psoriatic sample, respectively. The input and output neurons
are connected by the hidden layers of neurons. In order to avoid model
over-ﬁtting, the number of hidden layers was set to one in this study.
The rest of the parameters used the default values.
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Aneural network based binary classiﬁerwas evaluated using the fol-
lowing three performance measurements [33,34]. Let P = {P1, P2,…,
P91} and N = {N1, N2,…, N85} as the positive and negative data sets,
respectively. TP is the number of psoriatic samples predicted to be
psoriatic, and FN is the number of psoriatic samples incorrectly predict-
ed to be healthy. TN and FP are the numbers of healthy samples predict-
ed to be healthy and psoriatic, respectively. The classiﬁcation model's
sensitivity and speciﬁcity are deﬁned to be Sn = TP/(TP + FN) and
Sp = TN/(TN + FP), respectively. The model's overall accuracy is
Ac = (TP + TN)/(TP + FN + TN + FP).
A neural network classiﬁcation model may be over-ﬁtted if the num-
ber of features used in the model is similar to or larger than that of the
training samples. This can be overcome by restricting the number of se-
lected features and evaluating the classiﬁcation model's cross-validation
performance. This study measures how a classiﬁcation model performs
by the commonly used 10-fold cross-validation strategy, as similar to
[35–37]. Its principle is to randomly split the 91 psoriatic and 85 healthy
samples into ten equal-sized subsets P = {P1, P2,…, P10} and N = {N1,
N2,…, N10}, respectively. For the pair of psoriatic and healthy sample sub-
sets Pk and Nk, where k ϵ {1, 2,…, 10}, a single-hidden-layer feed-forward
neural network classiﬁer was trained over the data sets P\Pl and N\Nl,Fig. 1.Hierarchical clustering plots of the samples from the twomicroarray data sets for the raw
GSE13355 were colored in red and green, respectively. The three ﬁnally chosen features, i.e. 2
were highlighted as red in the right vertical panel.where l ≠ k, and the prediction performance was measured over the
data sets Pk and Nk. The overall prediction performances, Sn, Sp, and Ac,
were summed over 10 times of calculations.
3. Results
3.1. DWD adjustment results
The systematic batch bias between the two microarray data sets,
GSE14905 [15] and GSE13355 [16,17] used in this study, was corrected
by the DWD algorithm [20]. The samples from the two microarray data
sets were clearly partitioned into the two data sets in the unsupervised
hierarchical clustering, as shown in Fig. 1(A). This separation suggests
that the samples were more similar to those from the same microarray
data set than those from the other data set, and samples of the same phe-
notype labeling, i.e. healthy or psoriatic, have no correlations with each
other. Similar separation can be achieved by theﬁrst principle component
in the principle component analysis (PCA) algorithm [38,39], as shown in
Supplementary Fig. S1(a). The batch bias needs to be corrected, before the
two independently produced microarray data can be used as the cross-
validation data sets. By the DWD-based projection, the two data sets
were reasonably mixed together after removing the batch bias, as
shown in the dendrogram in Fig. 1(B). Supplementary Fig. S1(b) showsdata (A) before and (B) after the DWDbatch effect correction. The data sets GSE14905 and
27736_at (gene: C10orf99), 227735_s_at (gene: C10orf99) and 239430_at (gene: IGFL1),
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separate the samples from the two different microarray data sets, thus
supporting the hypothesis that the batch bias was corrected.
3.2. Gene sets determined by feature selection algorithms
Different feature selection algorithms rank the features with different
phenotype-association measurements, and we hypothesized that fea-
tures chosen by all the three feature selection algorithms, i.e. SVM-RFE,
ROC and Boruta, have stable discrimination power. We chose 80 features
top-ranked by each of the three algorithms SVM-RFE, ROC and Boruta.
The intersection of the three top-ranked feature lists consisted of 21
features, corresponding to 18 human genes, as shown in Fig. 2. The
probe set IDs, ofﬁcial gene symbols, and functional annotations of the
above chosen features/probe-sets were detailed in Supplementary
Table S2.
We further investigated the discriminating power of the combined
list of all the 21 features. The expression patterns of the 21 features
were visualized as the unsupervised hierarchical clustering heatmap
of all the 176 samples, as shown in Fig. 3. The 176 samples can be easily
separated into their correct labels, with only two psoriatic samples in-
correctly predicted as healthy. This visual separation gave a detection
accuracy Ac = 174/176–98.86% for the 176 samples. The 10-fold
cross-validation of the neural network binary classiﬁer rendered the
same prediction result. Fig. 3 also demonstrated that all of the 21
features (probe sets) were up-regulated in the psoriatic samples.
3.3. Robustness test of the binary classiﬁer
The prediction robustness of the binary classiﬁer was evaluated
using the Incremental Feature Selection (IFS) strategy. The selected 21
features were ranked by the averaged scores calculated from the three
feature selection algorithms as {f1, f2,…, f21}. We calculated the overall
accuracy Ac using the features {f1, f2,…, f1}, (i ≤ 21) over three indepen-
dent validations. The number of features iwas chosen, if the average ac-
curacy AvgAc over the three validations reaches the peak as shown in
Fig. 4. The three validation strategies are described below. For the two
independently generated microarray data sets, GSE14905 and
GSE13355, we ﬁrstly conducted a 10-fold cross-validation of the binary
classiﬁer over the combined data set, denoted here as 10FCV. In the sec-
ond validation strategy, we used GSE14905 as the training data set and
GSE13355 the test set to validate the classiﬁer, denoted here asFig. 2. The overlapping features top-ranked by the three feature selection algorithms. Each
of the three algorithms, i.e. Boruta, SVM-RFE and ROC, chooses 80 features. There are 21
features that are in the overlapping region of the three algorithms.tGSE14905. The third validation strategy tGSE13355 was deﬁned simi-
larly as tGSE14905. The latter two validations evaluated the stability of
the classiﬁcation model on data sets with batch effects.
Thebinary classiﬁer achieved thebest overall accuracies (99.81%) over
the three validation strategies, as shown in Fig. 4. The top one ranked fea-
ture, 227736_at (gene C10orf99), achieved 100% in Ac for both 10FCV and
tGSE13355 validations, but didn't work equally well on the tGSE14905
validation. The second best feature, 227735_s_at, also resides within
C10orf99. But the classiﬁer based on the two features, 227736_at and
227735_s_at, performed worse than 227736_at itself over the 10FCV val-
idation. The top three ranked features, 227736_at and 227735_s_at (gene
C10orf99) and 239430_at (gene IGFL1), produced a binary classiﬁer
which performed well with 99.43%, 100% and 100% in overall accuracies
(Ac) for the three validation strategies. A classiﬁer based onmore features
produced ﬂuctuated overall accuracies between 80% and 100% (Fig. 4).
The three features were highlighted in bold and blue font in Supplemen-
tary Table S2, whose functions are discussed in details below.
3.4. Enrichment analysis of differentially expressed genes
The Gene Ontology (GO) annotations were screened for the terms
enriched in the 21 psoriasis associated features (18 human genes), as
shown in Table 1. The enrichment analysis was conducted using the
system DAVID with default parameters (Evalue cutoff = E−2) [40].
The Pvalues of these multiple tests were statistically corrected by
Bonferroni and Benjamini algorithms [41]. Only the GO categories
with Pvalues ≤ 0.05 after both multi-test corrections were kept for fur-
ther analysis, as shown in Table 1. Genes involved in the development
and differentiation processes of the skin cells, in particular the
keratinocyte and epidermal cells, were signiﬁcantly enriched in the 21
features that were chosen by three different feature selection
algorithms. This result is consistent with the clinical observation that un-
controlled differentiation of the skin cells is psoriasis's major symptom
[42,43]. There is also a sub-cellular compartment, corniﬁed envelope
(GO:0001533 with Pvalue = 5.65E−03 after both correction algo-
rithms), which was enriched with 3 psoriasis associated genes.
4. Discussion
4.1. A robust prediction signature for psoriasis
This study aimed to establish a robust psoriasis prediction model,
based on the gene expression proﬁles of human samples. Multiple sets
of genes were proposed to be associated with psoriasis, or differentially
expressed in psoriasis samples [13–15,44]. Such gene sets consist of
dozens or even hundreds of candidate markers, which may potentially
be used for psoriasis diagnosis. However, psoriasis classiﬁcation model
study is scarce. To our knowledge, this study is theﬁrst of this kind in con-
structing a feed-forward neural network based psoriasis binary classiﬁer.
We hypothesized that the association between the marker features
and psoriasis is strong enough to pass the ﬁltering criteria of different fea-
ture selection algorithms. Thereforewe applied threewidely used feature
selection algorithms, i.e. SVM-RFE, ROC and Boruta, to screen the 27,336
features that passed the data quality ﬁltering criteria and have statistical
signiﬁcant variations between the disease and control samples. The top
80 features ranked by each of the three feature selection algorithms
with default parameters, i.e. SVM-RFE, ROC and Boruta, were retained
for further analysis. The intersection of these three lists resulted in 21 fea-
tures (probe sets) that belong to 18 human genes. Majority of the 21 fea-
tureswere known to be associatedwith the initiation anddevelopment of
psoriasis, as shown in Table 1 and Supplementary Table S2.
A comprehensive classiﬁcation validation was conducted to investi-
gate how a subset of these 21 features may be combined to build a
binary classiﬁer, which can perform equally well on different data
sets.We incrementally added one feature at a time to the feature subset
by the ranking order. We evaluated the feed-forward neural network
Fig. 3. The hierarchical clustering heatmap of samples based on expression patterns of the 21 features. Each row corresponds to a feature and each column corresponds to a sample. The
status of psoriasis or normal for each subject is shown with the above bar. The psoriatic and healthy samples are in red and blue, respectively.
52 P. Guo et al. / Genomics 103 (2014) 48–55classiﬁer with one hidden layer of nodes in three independent valida-
tion strategies, as described in the above section. The binary classiﬁers
based on the top one or two features excelled in some validations, but
were not stable enough on the other data sets. With one more feature,
the trained binary classiﬁer achieved the overall accuracies of 99.43%,
100% and 100% for the three validation strategies, respectively, and
the best averaged overall accuracy (99.81%) among all the incremental-
ly added feature subsets, as shown in Fig. 4.We also observed thatmore
features made the overall accuracies more ﬂuctuating.
In all, the binary classiﬁer trained over the top three ranked features
(two human genes, C10orf99 and IGFL1) represents a robust and highly
accurate psoriasis prediction model.
4.2. Functional insights of the two marker genes, IGFL1 and C10orf99
Psoriasis was regarded as a T-cell-driven disease with autoimmune
mechanisms as its primary cause [45]. This view was supported byFig. 4. Prediction accuracy assessment based on the feature subset in three scenarios by
the Incremental Feature Selection (IFS) strategy. The overall accuracy (Ac) values of the
validations 10FCV, tGSE14905 and tGSE13355 were plot in different line types. The
average accuracy is averaged over the three validation strategies for the number of
features i, and is plotted as a dash line with circle points.clinical data and genetic studies, such as HLA-C*06, ERAP1, the IL-23
pathway, and NF-κB signaling [46]. The PI3K/Akt pathway may be con-
tinuously sustained by the C10orf99 stimulus, promoted keratinocyte
proliferation, and increased the anti-apoptotic NF-κB signaling, which
not only resist psoriatic keratinocytes to cell death [47], but also trigger
cytokine expression resulting to inﬂammatory responses [48]. At
present, there exist conventional and biologic agents to treat psoriasis.
Conventional treatments include methotrexate, cyclosporine A, and
acitretin. Five biologic agents are FDA approved for psoriasis treatment:
alefacept (T-cell modulator), adalimumab, etanercept, ustekinumab
and inﬂiximab (TNF-α inhibitors) [49]. These biologic agents may only
control the development of the symptoms.
The psoriasis classiﬁcation model developed in this study suggested
an association between psoriasis and two marker genes, IGFL1 and
C10orf99. Amolecular pathway of psoriasis development wasmanually
curated from the literature [50,51], as shown in Fig. 5. IGFL1 is one of the
fourmembers of the human insulin growth factor (IGF)-like (IGFL) fam-
ily, which is the ligand of cell membrane associated receptor IGFLR1.
Structurally similar to the IGF family members, IGFLs comprise small
and secreted proteins (shorter than 80 aa on average in the mature
polypeptide) and contain 11 Cysteines including two CC motifs [52].
With other hormones or growth factors, IGFLs promote cell proliferation
and differentiation, and suppress apoptosis in various cell types [53].
The continuous stimulation of IGFL1 induces a prolonged association
of phosphatidylinositol 3 kinase (PI3K) with the IGFL1 receptor, which
was shown to be essential for IGFL1-induced cell proliferation, including
promoting DNA synthesis and increasing cell number [54].
Two IGFLR1 can dimerize when the growth factor IGFL1 is coupled
and induce auto-phosphorylation. The post-translational modiﬁcation
of IGFLR1 transduces the growth signal to the downstream PI3K/Akt
pathway. C10orf99 may be a serine/threonine kinase that can phos-
phorylate IGFLR1 and induce the same signal transduction, based on
multiple sources of evidences. The functional annotation of C10orf99
was not documented in various databases, such as UniProtKB [55] and
Human Protein Atlas [56]. We structurally aligned C10orf99 to the
known 3D structures using I-TASSER version 1.1 [57]. The top ﬁve en-
zyme homologs of C10orf99 were found belonging to the Enzyme
Table 1
Enriched Gene Ontology (GO) terms. Gene Ontology (GO) terms from the groups of biological process (BP), cellular component (CC) andmolecular function (MF), that were signiﬁcantly
enriched in the 21 selected features (probe sets).
Term Pvalue FC Bonferroni Benjamini
BP|GO:0031424 — keratinization 6.45E−06 96.8 8.13E−04 8.13E−04
BP|GO:0009913 — epidermal cell differentiation 3.07E−05 57.81 3.86E−03 1.29E−03
BP|GO:0030216 — keratinocyte differentiation 2.36E−05 63.07 2.98E−03 1.49E−03
BP|GO:0030855 — epithelial cell differentiation 2.09E−04 30.38 2.60E−02 6.57E−03
CC|GO:0001533 — corniﬁed envelope 2.18E−04 124.5 5.65E−03 5.65E−03
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2.7.11.1, 2.7.11.13 and 2.7.11.1). The best two matches (PDBs 3C4W
and 3C51) are G protein coupled receptor (GPCR) kinases (GRKs). The
best match, enzyme PDB 3C4W, has as little as 3.38 RMSD variation to
the predicted structure of C10orf99 as shown in Fig. 6 (within the rea-
sonable RMSD cutoff of 5.5 [58]), where RMSD is the root mean square
deviation between two 3D structures. GRK was proposed to facilitate
the phosphorylation of IGFLR1, and to activate the downstream PI3K/
Akt pathway [59]. By suppressing the GRK expression with siRNA,
Zheng et al. demonstrated that the decreased expression of GRK5/6
abolished IGFL1-mediated AKT activation, and GRK2 inhibition partially
inhibited AKT signaling [59]. IGFL1 binding to its receptor IGFLR1 can
stimulate the phosphorylation of the insulin receptor substrate (IRS)
[60] and activate the PI3K/Akt pathway [61]. Therefore, the elevated ex-
pression of C10orf99 can activate the downstream IGLF1-mediated AKT
pathway, as shown in Fig. 5. This hypothesis was supported by a num-
ber of recent studies at the genomics and epigenetics levels. C10orf99
was shown to be up-regulated by 1.7-fold in uninvolved skins of psori-
atic patients and even by 30-fold in the lesion skins [62]. The twomicro-
array data sets used in this study also showed the elevated expression of
C10orf99 in the psoriatic lesion skins [16,17]. The up-regulation ofFig. 5.Molecular pathway of psoriasis development. The details of the abbreviations are listed
receptor 1; IRS, insulin receptor substrate; C10orf99, chromosome 10 open reading frame
phosphoinositide 3 kinase, catalytic, alpha polypeptide; PIP2, phosphatidylinositol (4,5)-bisph
light polypeptide gene enhancer in B-cells; P, phosphate.C10orf99 in psoriasis was independently supported by the epigenetic
studies, which showed signiﬁcantly less methylation of C10orf99 in
the psoriatic samples compared to the healthy controls [63].
5. Conclusions
This study constructed a robust two-gene expression signature to
distinguish the psoriasis samples from the healthy ones. The functional
characterization of the two genes, IGFL1 and C10orf99, suggests that the
kinase IGFL1 activates the growth signal receptor C10orf99 by
phosphorylation, and triggering a growth signal to the cell proliferation
machinery. Further experiments will be conducted to investigate the
regulatory roles of IGFL1 and C10orf99 in the psoriasis pathogenesis,
and their potential use as psoriasis drug targets.
List of abbreviations used
DWD Distance Weighted Discrimination
RFE Recursive Feature Elimination
ROC receiver operating characteristic
TPR true positive rate
FPR false positive ratehere: IGFL1, insulin-like growth factor (IGF) like family member 1; IGFLR1, IGF-like family
99; P85, p85 regulatory subunit; P110α, PtdIns-3-kinase subunit p110-alpha; PI3K,
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